Loading...
XPAR
MEDCL
Market cap590mUSD
Jun 16, Last price  
15.49EUR
1D
0.26%
1Q
7.27%
IPO
113.66%
Name

Medincell SA

Chart & Performance

D1W1MN
P/E
—
P/S
42.88
EPS
—
Div Yield, %
—
Shrs. gr., 5y
10.49%
Rev. gr., 5y
52.61%
Revenues
12m
+20.79%
8,232,0008,533,0006,438,0001,443,0002,852,0008,186,0004,090,0009,889,00011,945,000
Net income
-25m
L-21.78%
622,000-3,561,000-9,571,000-19,687,000-23,915,000-18,986,000-24,806,000-32,009,999-25,038,000
CFO
-12m
L-53.10%
68,000-3,393,000-5,426,000-15,932,000-13,998,000-15,597,000-22,393,000-25,421,000-11,922,000
Earnings
Sep 12, 2025

Profile

MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company is based in Jacou, France.
URL
https://www.medincell.com/
IPO date
Oct 08, 2018
Employees
131
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
11,945
20.79%
9,889
141.78%
Cost of revenue
35,653
32,616
Unusual Expense (Income)
NOPBT
(23,708)
(22,727)
NOPBT Margin
Operating Taxes
88
(3,766)
Tax Rate
NOPAT
(23,796)
(18,961)
Net income
(25,038)
-21.78%
(32,010)
29.04%
Dividends
Dividend yield
Proceeds from repurchase of equity
23,296
810
BB yield
-8.55%
-0.33%
Debt
Debt current
6,161
43,455
Long-term debt
55,702
14,252
Deferred revenue
Other long-term liabilities
8,506
2,900
Net debt
41,966
50,786
Cash flow
Cash from operating activities
(11,922)
(25,421)
CAPEX
(324)
(1,027)
Cash from investing activities
(613)
1,254
Cash from financing activities
25,528
6,016
FCF
(22,857)
(18,302)
Balance
Cash
19,460
6,467
Long term investments
437
454
Excess cash
19,300
6,427
Stockholders' equity
(71,838)
(49,963)
Invested Capital
98,481
65,146
ROIC
ROCE
EV
Common stock shares outstanding
28,420
25,188
Price
9.59
-2.24%
9.81
32.21%
Market cap
272,543
10.30%
247,099
33.93%
EV
314,509
329,642
EBITDA
(21,989)
(21,062)
EV/EBITDA
Interest
4,617
3,932
Interest/NOPBT